Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors.

Autor:	Laface C; Azienda Sanitaria Provinciale, Reggio Calabria (RC), Italy., Fina E; Thoracic Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy., Ricci AD; Medical Oncology Unit, National Institute of Gastroenterology, IRCCS 'S. de Bellis' Research Hospital, Castellana Grotte, Italy., Guven DC; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.; Medical Oncology Clinic, Elazig City Hospital, Health Sciences University, Elazig, Turkey., Ambrogio F; Section of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy., De Summa S; Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori, 'Giovanni Paolo II', Bari, Italy., Vitale E; Scientific Directorate, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Massafra R; Scientific Directorate, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Brunetti O; S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Rizzo A; S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
Jazyk:	angličtina
Zdroj:	Expert opinion on biological therapy [Expert Opin Biol Ther] 2024 Dec; Vol. 24 (12), pp. 1363-1374. Date of Electronic Publication: 2024 Nov 18.
DOI:	10.1080/14712598.2024.2431088
Abstrakt:	Introduction: Recently, immunotherapy has offered new hope for treating biliary tract cancer (BTC). However, several issues are to be considered, including the lack of validated predictive biomarkers that could help to identify patient groups which are most likely to benefit from such therapeutic approaches. Areas Covered: In the current article, we will provide an overview of recent results and ongoing and future research directions of immunotherapy in BTC, with a special focus on recently published, practice-changing data, and ongoing active and recruiting clinical trials. Expert Opinion: At this moment, dozens of clinical trials in phases I to III are evaluating the role of cancer immunotherapy in this setting, with the hope of adding more therapeutic options for BTC patients. Future research must focus on the development of novel agents and combinations, but the validation of biomarkers remains an urgent need. As more research results emerge, novel combinatorial strategies are destined to further transform the treatment paradigm for this heterogeneous and aggressive tumor type.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu